Beranda › Tumor Neuroendokrin
Uji klinis Tumor Neuroendokrin yang merekrut di AS
40 studi untuk Tumor Neuroendokrin merekrut peserta di lokasi di seluruh Amerika Serikat.
Kota dengan studi terbanyak
- Washington, DC11 studi
- Philadelphia, PA11 studi
- Rochester, MN9 studi
- Salt Lake City, UT8 studi
- Houston, TX8 studi
- Columbus, OH8 studi
- St. Louis, MO8 studi
- Cleveland, OH7 studi
- Miami, FL7 studi
- Chicago, IL7 studi
- Cedar Rapids, IA7 studi
- New York City, NY7 studi
- Detroit, MI7 studi
- Lexington, KY7 studi
- Dallas, TX6 studi
- Nashville, TN6 studi
- Omaha, NE6 studi
- Charlottesville, VA6 studi
- Portland, OR6 studi
- Mountain View, CA5 studi
- Milwaukee, WI5 studi
- Jacksonville, FL5 studi
- Tampa, FL5 studi
- Seattle, WA5 studi
- Atlanta, GA5 studi
- San Francisco, CA5 studi
- Los Angeles, CA5 studi
- Boston, MA5 studi
- Grand Rapids, MI5 studi
- Ann Arbor, MI4 studi
- Baltimore, MD4 studi
- Buffalo, NY4 studi
- Durham, NC4 studi
- Baldwin Park, CA4 studi
- Fargo, ND4 studi
- Phoenix, AZ4 studi
- Arlington, VA4 studi
- San Diego, CA3 studi
- New Orleans, LA3 studi
- Hartford, CT3 studi
Berdasarkan negara bagian
- Alabama3 studi
- Arizona7 studi
- California14 studi
- Colorado4 studi
- Connecticut5 studi
- Florida12 studi
- Georgia6 studi
- Illinois8 studi
- Iowa8 studi
- Kentucky7 studi
- Louisiana6 studi
- Maryland13 studi
- Massachusetts7 studi
- Michigan11 studi
- Minnesota11 studi
- Missouri9 studi
- Nebraska6 studi
- New Mexico3 studi
- New York9 studi
- North Carolina5 studi
- North Dakota4 studi
- Ohio14 studi
- Oregon6 studi
- Pennsylvania12 studi
- Tennessee7 studi
- Texas11 studi
- Utah8 studi
- Virginia7 studi
- Washington5 studi
- Wisconsin7 studi
Studi yang baru diperbarui
Teks studi resmi (Bahasa Inggris)
A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity
Menerima pesertaFase 2
Usia 18 hingga 120 · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT06406465Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)
Menerima pesertaFase 1/2
Usia 18 hingga 100 · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT04086485Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
Menerima pesertaFase 2/3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 29 Sep 2026 · NCT06943755Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
Menerima pesertaFase 2
Usia 18 hingga 72 · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT03412877A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT06881992Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
Menerima pesertaFase 1
24 Months – 18 Years · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06441331Tissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carcinoma (ACC)
Menerima pesertaStudi observasional
Usia 18 hingga 120 · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT05237934EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer.
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Sep 2026 · NCT06263088Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Sep 2026 · NCT07087054Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Sep 2026 · NCT07165132Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
Menerima pesertaFase 2
Usia 18 hingga 100 · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT03206060Project: Every Child for Younger Patients With Cancer
Menerima pesertaStudi observasional
Hingga usia 25 · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT02402244The Use of Guarana to Treat Fatigue in Patients With Neuroendocrine Tumors and Gynecologic Cancers (Guarana Fatigue)
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 7 Agu 2026 · NCT07151391An Investigational Scan ([68Ga] Ga-FAPI-04 PET/CT) for the Imaging of Patients With High-Grade Neuroendocrine Cancer
Menerima pesertaFase awal 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 31 Jul 2026 · NCT07132645A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 31 Jul 2026 · NCT07129252Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Jul 2026 · NCT05263050Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
Menerima pesertaFase 1/2
Usia 18 hingga 99 · Semua jenis kelamin · Diperbarui 13 Jul 2026 · NCT05000294Integrated Cancer Repository for Cancer Research
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 19 hingga 110 · Semua jenis kelamin · Diperbarui 29 Jun 2026 · NCT02012699A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors
Menerima pesertaFase 1
Usia 18 hingga 120 · Semua jenis kelamin · Diperbarui 15 Jun 2026 · NCT06041516Breathing Practice for Brain and Mental Health in Cancer and Neurodegenerative Diseases
Menerima pesertaSukarelawan sehat diterima
Usia 18 hingga 85 · Semua jenis kelamin · Diperbarui 10 Jun 2026 · NCT06788886CapTemY90 for Grade 2/3 NET Liver Metastases
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 4 Jun 2026 · NCT04339036A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
Menerima pesertaFase 1/2
Usia 12 ke atas · Semua jenis kelamin · Diperbarui 27 Mei 2026 · NCT03093116Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
Menerima pesertaFase 1/2
Usia 18 hingga 90 · Semua jenis kelamin · Diperbarui 14 Mei 2026 · NCT05636618SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Apr 2026 · NCT06889493Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors
Menerima pesertaFase 2
Usia 12 ke atas · Semua jenis kelamin · Diperbarui 20 Apr 2026 · NCT04074135Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.